Analysts at Bank of America assumed coverage on shares of Metsera (NASDAQ:MTSR – Get Free Report) in a report issued on Tuesday,Benzinga reports. The firm set a “buy” rating and a $38.00 price target on the stock. Bank of America‘s price target points to a potential upside of 27.47% from the company’s current price.
Separately, Evercore ISI initiated coverage on shares of Metsera in a report on Tuesday. They issued an “outperform” rating on the stock.
Get Our Latest Research Report on Metsera
Metsera Price Performance
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
See Also
- Five stocks we like better than Metsera
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Confluent: How Data Streaming May Transform AI
- Why Are Stock Sectors Important to Successful Investing?
- The Behemoth BlackRock’s Next Trillion Comes From Private Assets
- Insider Trades May Not Tell You What You Think
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
